Idhifa (enasidenib) is an oral targeted treatment for acute myeloid leukemia (AML) that works by blocking the enzyme isocitrate dehydrogenase-2 (IDH2). This helps young red blood cells (blasts) in your bone marrow to mature into healthy red and white blood cells and platelets.